Karbis (Candesartan Cilexetil)

Candesartan cilexetil is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk.
• Heart failure: decreases mortality and hospitalisation by reducing cardiac workload.
• Diabetic nephropathy: slows progression of renal impairment in adults with type 2 diabetes.

• Candesartan cilexetil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure and cardiac afterload.

Candesartan cilexetil is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: feeling unusually tired or weak.
• Nasopharyngitis: upper respiratory tract infection symptoms.
• Diarrhoea: loose stools without blood.
• Cough: occasional dry cough.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or throat requiring emergency care.
• Hyperkalaemia: elevated serum potassium that may cause cardiac arrhythmia.
• Acute renal impairment: sudden decrease in kidney function.
• Hepatic injury: abnormal liver enzymes or jaundice.
• Severe hypotension: markedly low blood pressure causing fainting.
• Myocardial infarction: rare reports of heart attack.

Before initiating therapy, clinicians should consider several safety measures.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with existing kidney disease.
• Serum potassium: monitor potassium levels to detect hyperkalaemia.
• Pregnancy avoidance: do not use in pregnancy due to fetal risk (Category D).
• Hepatic impairment: use with caution in patients with liver disease.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Candesartan cilexetil may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• ACE inhibitors or other ARBs: concurrent use can cause additive renal dysfunction and hyperkalaemia.
• Aliskiren in diabetic patients: combined use increases risk of renal impairment and hypotension.
• Potassium‑sparing diuretics: may precipitate dangerous hyperkalaemia.
• High‑dose NSAIDs: can reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: candesartan can raise lithium concentrations, requiring serum level checks.
• Cyclosporine: may increase serum creatinine; monitor kidney function.
• Thiazide diuretics: may enhance antihypertensive effect, watch for hypotension.
• Rifampin: may lower candesartan levels, reducing efficacy.
• NSAIDs (regular dose): monitor renal function and blood pressure.